1. Technical Field
Devices and methods for fixation of tissue are disclosed. More specifically, the devices and methods can be for inter body vertebral fusion of vertebrae or fusion of other bones to one another.
2. Background of the Art
A vertebroplasty device and method that eliminates or reduces the risks and complexity of the existing art is desired. A vertebroplasty device and method that may reduce or eliminate the need to inject a liquid directly into the compression fracture zone is also desired.
Other ailments of the spine result in degeneration of the spinal disc in the intervertebral space between the vertebral bodies. These include degenerative disc disease and traumatic injuries. In either case, disc degeneration can cause pain and other complications. Conservative treatment can include non-operative treatment requiring patients to adjust their lifestyles and submit to pain relievers and a level of underlying pain. Operative treatment options include disc removal. This can relieve pain in the short term, but also often increases the risk of long-term problems and can result in motor and sensory deficiencies resulting from the surgery. Disc removal and more generally disc degeneration disease are likely to lead to a need for surgical treatment in subsequent years. The fusion or fixation will minimize or substantially eliminate relative motion between the fixed or fused vertebrae. In surgical treatments, adjacent vertebra can be fixated or fused to each other using devices or bone grafts. These may include, for example, screw and rod systems, interbody spacers (e.g., PEEK spacers or allograft bone grafts) threaded fusion cages and the like.
Some fixation or fusion devices are attached to the vertebra from the posterior side. The device will protrude and result in additional length (i.e., needed to overlap the vertebrae) and additional hardware to separately attach to each vertebrae. Fusion cages and allografts are contained within the intervertebral space, but must be inserted into the intervertebral space in the same dimensions as desired to occupy the intervertebral space. This requires that an opening sufficient to allow the cage or graft must be created through surrounding tissue to permit the cage or graft to be inserted into the intervertebral space.
A spinal fixation or fusion device that can be implanted with or without the need for additional hardware is desired. Also desired is a fixation or fusion device that can be deployed in a configuration where overlapping the fixated or fused vertebrae is not required.
Also desired is an intervertebral device the may be inserted in to the intervertebral space at a first smaller dimension and deployed to a second, larger dimension to occupy the intervertebral space. The ability to insert an intervertebral spacer at a dimension smaller than the deployed dimension would permit less disruption of soft and boney tissue in order to access the intervertebral space.
A device that can replace or supplement the screw or rod elements of a typical fusion system is disclosed. The device can be placed in the inter-vertebral space to fuse adjacent vertebrae and/or create a bone mass within the inter-vertebral space in a patient's spine.
The device can be less invasive than typical existing devices. For example, the device can be in a compacted (i.e., small) configuration when inserted into a patient and transformed into an expanded (i.e., large) configuration when positioned at the target site. For example, the device can be expanded when the device is between the inferior and superior vertebral body surfaces. The device can create less soft tissue (e.g., bone) disruption than a typical fusion system. The device in an expanded configuration can improve anchoring within the joint, structural stability, and create an environment for bone healing and growth leading to fusion between adjacent vertebrae.
During deployment into tissue (e.g., bone), one, two or more holes can be drilled into the target site to create a deployment hole in which to insert the device. The deployment hole can be round or non-round (e.g., by drilling more than one overlapping or adjacent hole, or crafting a square or rectangular hole), for example to substantially match the transverse cross-section of the device in a contracted configuration.
The device can be cannulated, for example having a lateral (i.e., transverse or latitudinal) and/or lengthwise (i.e., longitudinal) channel through the device. The device can be deployed over a wire or leader, such as a guidewire. The device can be slid over the guidewire, with the guidewire passing through the longitudinal channel of the device.
a, 39b and 39c are bottom perspective, end and side views, respectively, of a variation of the device in a longitudinally expanded configuration.
a, 40b, and 40c are bottom perspective, end and side views, respectively, of the device of
a through 41d are top, top perspective, side, and bottom perspective views, respectively, of a variation of the device in a longitudinally expanded and radially contracted configuration.
a through 42c are top, side and top perspective views, respectively, of the variation of the device of
a through 43d are top, top perspective, side, and bottom perspective views, respectively, of the device of
a through 44c are top, side and top perspective views, respectively, of the variation of the device of
a and 45b are top and top perspective views, respectively, of a variation of the bottom plate.
a and 46b are bottom and bottom perspective views, respectively, of a variation of the top plate.
a and 47b are top perspective and bottom perspective exploded views, respectively, of the variation of the device of
a through 48d are top, top perspective, side, and bottom perspective views, respectively, of a variation of the device in a longitudinally expanded and radially contracted configuration.
a through 49d are top, top perspective, side, and bottom perspective views, respectively, of the device of
a and 50b are side and top perspective views of the device of
a and 51b are top and top perspective views, respectively, of a variation of the bottom plate.
a through 52c are bottom, bottom perspective, and end perspective views, respectively, of a variation of the top plate.
a through 53d are top, top perspective, side, and bottom perspective exploded views, respectively, of the variation of the device of
c and 53d illustrate the device upside down compared to the orientation shown in
a and 55b illustrate visualizations of variations of the device deployed into the spine between adjacent vertebrae.
a and 56b illustrate variations of methods for inserting one or more devices into one or more target sites.
A device 2 is disclosed that can be inserted into a target site 264 with the device 2 in a compressed or contracted (i.e., small) configuration. Once positioned in the deployment site, the device 2 can be transformed into an expanded (i.e., larger, bigger) configuration. The device 2 can be inserted and expanded in orthopedic target sites 264 for fixation and/or support. For example, the device 2 can be inserted and expanded over a guidewire between adjacent vertebral bodies.
The slidable attachment of the top and base plates can permit the base 138 to move radially (with respect to the longitudinal axis 4) relative to the top and vice versa.
The top plate 6 can have a high-friction and/or low-friction texture extending radially away from the base 138. For example, the top plate 6 can have one or numerous rows of top teeth 118. The bottom plate 10 can have a high-friction and/or low-friction texture extending radially away from the base plate. For example, the bottom plate 10 can have one or numerous rows of bottom teeth 104. The top teeth 118 and the bottom teeth 104
The top plate 6 can have one or more side ports 114 and/or top ports. The base plate can have one or more base ports 120 and/or side ports 114. The base ports 120, side ports 114, and/or top ports can be ingrowth channels 28. The ports can be circular, square, triangular, oval, elongated in the longitudinal direction, elongated in the radial direction, or combinations thereof.
The top plate 6 can have a top chamfer 156. The base plate can have a base chamfer. The chamfers can be atraumatic edges. The chamfers can extend along the perimeter of the base 138 and/or top.
The device 2 can have one, two or more wedges, for example a first or distal side ramp 96 on a first longitudinal side (e.g., the distal side) of the base plate and a second or proximal side ramp 108 on a second longitudinal side (e.g., the proximal side) of the base plate. The side ramps 96 and 108 can be configured to be slidably attachable to the base plate 10 and/or the top plate 6. The wedges or ramps 96 and 108 can be separate from each other. The ramps 96 and 108 can move independent of each other. The ramps 96 and 108 can be constrained by the top and bottom plates 6 and 10 to move concurrently and at the same rate in opposite directions. The angled faces of the ramps 96 and 108 can face each other. The “pointed” ends of the ramps 96 and 108 can point toward each other.
The ramps 96 and 108 and top plate 6 can be brought within proximity of the base plate 10. The ramps 96 and 108 can be slidably attached to the base plate 10. The ramps 96 and 108 can have ramp second tongues and grooves 98. The base plate 10 can have one or more base tongues and grooves 106. The ramp second tongues and grooves 98 can be configured to slidably attach to the base tongues and grooves 106.
The ramps 96 and 108 can be configured to be slidably attachable to the top plate 6. For example, the ramps 96 and 108 can have ramp first tongues and grooves 100. The top plate 6 can have top tongues and grooves 284. The ramp first tongues and grooves 100 can slidably engage the top tongues and grooves 284.
The first tongues and grooves can be at a ramp angle 136 with respect to the second tongues and grooves. The ramp angle 136 can be from about 15° to about 75°, more narrowly from about 30° to about 60°, for example about 45°.
One or more of the ramps 96 and 108 can have a ramp locking plate port 110. The ramp locking plate ports 110 can each be configured to receive a ramp locking plate. The ramps 96 and 108 can each have ramp ports, such as the threaded ramp ports. The threaded ramp ports can pass through the ramps 96 and 108, for example opening into the ramp locking plate port 110.
When the device 2 is in a deployed configuration in vivo, the device 2 can be partially or substantially filled with a liquid, gel, or solid (e.g., in small parts or granules) filler 262 material, or combinations thereof, such as bone morphogenic powder or any other material disclosed herein or combinations thereof. The filler 262 material can contact or be in near contact with the surrounding tissue near the edge of the ports, for example where the plate 286 is thinned. The filler 262 can be inserted into the device 2 before, and/or during (i.e., prepacked), and/or after the device 2 is inserted and/or expanded in the target site.
As the device 2 is expanded and contracted, the volume of the interior channel of the device (i.e., defined between the top and base plates and the opposing ramps) can remain constant. For example, filler can be inserted into the device 2 before the device is radially expanded. The device 2 can be longitudinally contracted and radially expanded (e.g., expanded in height). The ratio of the volume of filler to the volume of the interior channel of the device can then remain substantially constant as the device is radially expanded. For example, the decrease in volume of the interior channel of the device caused by the contracting ramps can be substantially equivalent to the increase in volume of the interior channel of the device 2 caused by the radially expanding top and base plates.
The latch top 288 can be configured to allow the top to pass over the latch 130. For example, the latch top 288 can be rounded and configured to push radially outward and clear of the top plate 6 when the top is pressed down into the latch top 288. The latch bottom 134 can be configured to grasp or otherwise attach to the top when the top is translated to a particular location into the base plate.
The stability bars 102 can be configured to resiliently bend radially outward and/or inward.
The wall of the base groove 146 can have an outwardly slanted configuration relative to the height of the wall of the base groove 146 from the bottom of the base plate.
The ramp gap 140 can be substantially closed. The ramp gap height 150 can be substantially about 0. The side ramps can be substantially friction fit along the base plate. For example, the friction in this configuration can be created along the top surface of substantially the entire base plate including the top of the base tongue 148, and the bottom surface of substantially the entire side ramps.
As the side ramp is pushed, as shown by arrows, toward the base plate, the ramp second tongues 144 can be pressed between the base grooves 146, for example, frictionally fitting the side ramps into the base plate. The base grooves 146 can be tapered, as shown, to force the ramp second tongues 144 to wedge fit or press fit into the base grooves 146 when the side ramp is pushed towards the base plate.
The side ramps can have less friction with the base plate in the configuration of the expandable support device 188 of
The ramp bottom teeth 152 and/or base interior teeth 154 can be unidirectionally or bidirectionally oriented (i.e., providing additional resistance against movement in one direction, or substantially the same resistance against movement in either direction).
As the side ramp translates, as shown by arrows, with respect to the base plate, the ramp gap height 150 is substantially non-zero, as shown in
In place of, or in addition to, the ramp bottom teeth 152 and/or the base top teeth, the respective surfaces can have high friction surfaces, for example a textured (e.g., knurled) surface and/or coated with a high friction material. The respective surfaces can also be smooth, having no teeth or texturing.
The side ramp can be pulled away from the base plate by reducing the compressive force between the side ramp and the base plate and pulling or pushing the side ramp.
The side ramp can have a belt and suspenders lock with the base plate.
The locking pin 162 can be configured to limit the vertical expansion of the device 2. For example, the locking pin 162 can be configured to substantially prevent the device 2 from disassembling.
A biocompatible adhesive or epoxy can be applied to the pin thread 168, threaded ramp port, abutment end 174, ramp abutment section 180, or combinations thereof.
The locking pin channel 164 can have locking pin ports 166 through the top, and/or bottom plates, and/or either or both side ramps.
Two locking pin channel 164 can be located on opposite sides of the threaded ramp port. The locking pin channels 164 and ports can have a circular cross-section (i.e., be cylindrical), as shown in
One or both of the ramps 96 and 108 can have first fixing teeth 192. The first fixing teeth 192 can be in contact with the top and/or the bottom. The top and/or the bottom (shown as bottom only) plates 286 can have second fixing teeth 190.
The first fixing teeth 192 can mechanically interact with the second fixing teeth 190 to allow relative translation in a first direction. The first fixing teeth 192 and the second fixing teeth 190 can interact to obstruct (e.g., by interference fitting the first fixing teeth 192 against the second fixing teeth 190) relative translation in a second direction. For example, the fixing teeth can obstruct the side ramps from moving longitudinally away from each other (i.e., and obstruct the top from moving closer to the bottom). Also for example, the fixing teeth can allow relative translation of the side ramps toward each other (i.e., and allow the top to move away from the bottom).
The second side ramp 108 can have a first end 186. The first end 186 can be configured to dissect tissue. The first end 186 can have a blunt or sharp point.
The second side ramp 108 can have a tool connector 184, such as an externally and/or internally threaded cylinder extending longitudinally from the second side ramp 108 away from the first side ramp 96. The tool connector 184 can be configured to removably attach to a deployment tool 80.
The first side ramp 96 and second side ramp 108 can be longitudinally compressed toward each other. For example, an external deployment tool 80 can be attached to the first side ramp 96 and second side ramp 108 and apply a compressive force. The base 138 and top plates 6 can expand away from each other.
The first fixing teeth 192 can unidirectionally interference fit the second fixing teeth 190. The unidirectional interference fit of the first fixing teeth 192 and the second fixing teeth 190 can substantially impede or prevent the opposite ramps 96 and 108 from moving longitudinally away from each other, for example, therefore impede or preventing compression 196 of the top toward the bottom and vice versa.
The unidirectional interference fit of the first fixing teeth 192 and the second fixing teeth 190 can allow the opposite ramps 96 and 108 to move longitudinally toward each other, for example, therefore allowing the top to expand away from the bottom and vice versa.
The expandable support devices 188 can have textured and/or porous surfaces for example, to increase friction against bone surfaces, and/or promote tissue ingrowth. The expandable support devices 188 can be coated with a bone growth factor, such as a calcium base 138.
a through 39c illustrate that the bottom ports can be one or more circular ports, for example six ports. The bottom ports can be aligned in a single row parallel with the longitudinal axis of the device 2.
The side ports 114 can open against the edge of the top plate 6 on one or more sides (e.g., the bottom sides, as shown) of the side ports 114.
The top plate 6 can have top plate side teeth 198 on the external lateral sides of the top plate 6. The bottom plate 10 can have bottom plate side teeth 202 on the external lateral sides of the bottom plate. The top plate side teeth 198 and/or the bottom plate side teeth 202 can be oriented from the top to the bottom of the device 2 (i.e., perpendicular to the longitudinal axis of the device 2). The top plate side teeth 198 can be aligned with the bottom plate side teeth 202.
The external lateral sides of the first side ramp 96 and/or second side ramp 108 can have ramp side teeth 200. The ramp side teeth 200 can be oriented parallel with the longitudinal axis of the device 2. The top plate side teeth 198 and/or the bottom plate side teeth 202 can be oriented perpendicular to the orientation of the ramp side teeth 200.
a through 40c illustrate that the top plate 6 and/or bottom plate 10 can be expanded away from each other in the directions of the orientation of the longitudinal axes of the top plate side teeth 198 and the bottom plate side teeth 202. The first and/or second side ramps 108 can be contracted toward one another in the direction of the orientation of the longitudinal axis of the ramp side teeth 200 of the first and second side ramps 108. The top plate side teeth 198, bottom plate side teeth 202, and ramp side teeth 200 can act as low-friction rails 42 against surrounding tissue when the device 2 is radially expanded at the target site 264.
The side ports 114 that open to the bottom edge of the top plate 6 can create a single side port 114 that can extend to the bottom plate.
The plates 286 and wedges can be rigid or exhibit ductile or deformable expansion during deployment. The transverse cross-section of the device 2 can be non-round. For example, the device 2 can have a square or rectangular transverse cross-section. The device 2 can have a substantially triangular or quadrilateral (e.g., trapezoidal) cross-section. The device 2 can have a round, hexagonal, octagonal, or other transverse cross-sectional configuration.
a through 41d illustrate that the device 2 can be curved, rounded (e.g., a continuous curvature along the entire length) or bent (e.g., at one or more angles at specific, discrete positions along the length). Any or all of the components of the device 2 can be curved, for example the top plate 6, bottom plate 10, a distal ramp 96, the proximal ramp 108, and combinations thereof. During use, the device 2 can be inserted into a target site, for example intervertebrally, rotating and translating the device 2, so the concave aspect of the curvature can be positioned to miss nearby sensitive tissue (e.g., the spinal cord) during placement.
The longitudinal axis of the device 2 can have a device radius of curvature 300. The device radius of curvature 300 can be from about 0.5 cm (0.2 in.) to about 40 cm (16 in.), more narrowly from about 1 cm (0.4 in.) to about 20 cm (8 in.), yet more narrowly from about 1.9 cm (0.75 in.) to about 7.0 cm (2.75 in.), for example about 3.2 cm (1.25 in.).
The proximal ramp 108 can have one or more proximal protrusions 304. For example, a single protrusion can extend proximally from the proximal ramp 108 centered with or asymmetric or off-center (as shown) to the longitudinal axis 4. The protrusion 304 can have a proximal ramp hole 302a, for example extending from the top of the protrusion 304 part or all of the way through the protrusion 304.
A deployment tool can releasably or fixedly attach to the proximal ramp hole 302a and/or protrusion 304. For example, the deployment tool can be rotatably attached to the proximal ramp hole 302a. For example, the deployment tool can have a removable pin that can be inserted into the hole proximal ramp hole 302a. The pin, still fixed to the deployment tool, can then be press fit (e.g., friction fit or interference fit) or rotated inside of the hole 302a, acting as a rotatable hinge. The pin can rotationally stabilize the device 2.
The pin can act as a stabilization device. The deployment tool can press on one or both sides of the protrusion 304 to rotate the device 2 about the proximal ramp hole 302a.
The distal ramp 96 can have a distal ramp keyhole 302b. The distal ramp keyhole 302b can extend from the top of the distal ramp 96 part or all the way through the distal ramp 96. The distal ramp keyhole 302b can be cylindrical (as shown), square, triangular, oval, rectangular, or star-shaped in cross section. An attachment key 308 can be inserted into the distal ramp key hole 302b, as shown by arrow in
The attachment key 308 can have the same cross-section as the distal ramp key hole 302b.
The locking pin 162 can be straight (as shown) or curved, such as having a substantially equal radius of curvature to the longitudinal axis. The locking pin 162 can have a proximal locking head plate or tool interface proximal section 290a that can extend proximally of the proximal ramp 108 when the device 2 is in a radially contracted and longitudinally expanded configuration. The locking pin 162 can be fixedly or detachably attached to the distal ramp 96.
a through 42c illustrate that the locking pin 162 can have an adjustable length. The locking pin 162 can have a smaller cylinder or proximal locking pin shaft 170a with radially outer threads and a larger outer cylinder or distal locking pin shaft 170b with radially inner threads. The smaller cylinder 170a can helically (e.g., threadably, as a screw or bolt) engage the larger cylinder 170b (e.g., as a nut).
The outside of the smaller cylinder 170a and the inside of the larger cylinder 170b can have a set of slidably engaging longitudinal ribs, slides, rails, guides, or combinations thereof.
The smaller cylinder 170a can be spring loaded with respect to the larger cylinder 170b. The inside of the locking pin 162 can have hydraulic fluid and an internal seal and/or piston so the locking pin 162 can act as a hydraulic damper or shock absorber.
The locking pin 162 can have a distal locking head or plate 290b. The distal locking head 290b can have a larger diameter than the diameter of the distal locking pin shaft 170b and distal ramp port 94a. The distal locking head 290b can be releasably attached to or fixed in or distal to the distal ramp port 94a.
The locking pin 162 can have a proximal locking head or plate 290a. The proximal locking head 290a can have a larger diameter than the diameter of the proximal locking pin shaft 170a and the proximal ramp port 94b. When the locking pin 162 is shortened, the proximal locking pin head 170a can abut or interference fit with the proximal ramp 108, pushing the proximal ramp 108 toward the distal ramp 96, longitudinally contracting and radially expanding the device 2.
The distal locking head 290b can have a key interface 306. The key interface 306 can be a notch, divot, threads, other engagement feature, or combinations thereof. The key interface 306 can slidably receive the attachment key 308, for example after the attachment key 308 is delivered into the distal keyhole 302b. The attachment key 308 can fix the locking pin 162 to the distal ramp 96, for example transferring force from the distal locking plate 290a to the distal ramp, capable of translating the distal ramp 96 proximally and distally with respect to the proximal ramp 108 when the length of the locking pin 162 is expanded and contracted.
a through 43d and 44a through 44c illustrate that the locking pin 162 can be attached to the distal ramp 96. The locking pin 162 can be longitudinally shortened. The distal ramp 96 can be contracted toward the proximal ramp 108, resulting in a longitudinal contraction of the device and a radial (e.g., height) expansion between the top plate 6 and the bottom plate 10. The ramps 96 and 108 can longitudinally contract along a straight or curved path (e.g., correlating with the shape of the grooves in the top plate, ramps and base plate) toward the center of the device 2.
The top plate 6 can extend in a parallel or non-parallel plane away from the bottom plate 10. A compressive force can be exerted between the proximal and distal ramps 108 and 96 along the longitudinal axis 4.
The attachment key 308 is not shown in
a and 45b illustrate that the base plate 10 can have proximal base grooves 106a and distal base grooves 106b. The proximal base grooves 106a can be a separate groove than the distal base grooves 106b. The proximal and distal base grooves 106a and 106b can be substantially straight (as shown) or curved.
The longitudinal axis of the proximal base grooves 106a and the longitudinal axis of the distal base grooves 106b can form a base groove angle 310. The base groove angle 310 can be from about 125° to about 175°, more narrowly from about 140° to about 160°, for example about 154°.
a and 46b illustrate that the top plate 6 can have proximal top grooves 284a and distal top grooves 284b. The proximal top grooves 284a can be separate from the distal top grooves 284b. The top grooves 284a and 284b can be substantially straight (as shown) or curved.
The longitudinal axis of the proximal top grooves 284a and the longitudinal axis of the distal top grooves 294b can form a top groove angle 312. The top groove angle 312 can be equal to the bottom groove angle 310.
a and 47b illustrate that the components of the device 2 can be slidably and rotatably assembled.
The outer locking pin shaft 170b can have an outer locking pin shaft channel 314. The inner locking pin shaft 170a can screw, slide, clip or otherwise engage into the outer locking pin shaft channel 314. The inner locking pin shaft 170a can be longitudinally translated within the locking pin shaft channel 314, for example by rotating the inner locking pin shaft 170a with respect to the outer locking pin shaft 170b. The total length of the locking pin 162 can be adjusted.
a through 48d and 49a through 50a illustrate that the device can have a radius of curvature 300. A compressive force can be exerted onto the ramps 96 and 108 along the longitudinal axis 4. For example, the locking pin and/or deployment tool can be flexible and/or have a rigid shape with a radius of curvature that matches the radius of curvature 300 of the device 2.
The ramps 96 and 108 can longitudinally contract along a curved path, such as along the longitudinal axis 4, toward the center of the device 2. During radial expansion, the top plate 6 can extend in a parallel plane away from the bottom plate 10.
The distal ramp 96 can have threading on inside of a distal ramp port 94a. The distal ramp port 94a can be aligned with the longitudinal axis 4.
The proximal ramp 108 can have threading on the radial exterior and/or interior of the tool connector 184. The proximal ramp 108 can have the tool connector 184, for example extending proximally from the remainder of the device 2. The tool connector 184 can be a cylindral proximal extension from the proximal ramp 108. The threading on the radial outside of the tool connector 184 can, for example, removably attach to a deployment tool.
a and 50b illustrate that the device can be assembled by sliding the iramps 96 and 108 onto the base plate. The ramps 96 and 108 can then be contracted to close to or at their respective inner-most positions on the base plate 10. The top plate 6 can then be delivered, as shown by arrow, onto the ramps 96 and 108. The ramps 96 and 108 can then be slid outward, extending away from the opposite ramp, as shown by arrows, engaging the top plate and pulling the top plate and the bottom plate together.
a and 51b illustrate that the inner base groove 106′ and/or outer base groove 106″ can be curved along a part or the entire length of the respective base grooves 106. The inner base groove 106′ can have an inner base groove radius of curvature 316″ from about 1.3 cm (0.5 in.) to about 6.4 cm (2.5 in.) for example about 2.5 cm (1.0 in.). The outer base groove 106″ can have an outer base groove radius of curvature 316″ from about 2.5 cm (1.0 in.) to about 7.6 cm (3.0 in.), for example about 3.8 cm (1.5 in.).
a through 52c illustrate that the inner proximal and distal top grooves 284a′ and 284b′ and outer proximal and distal top grooves 284a″ and 284b″ can be curved along a part or the entire length of the respective grooves.
The inner top grooves 284a′ and 284b′ can have inner top groove radii of curvature 318′ from about 1.3 cm (0.5 in.) to about 6.4 cm (2.5 in.) for example about 2.5 cm (1.0 in.). The inner top groove radii of curvature 318′ can be the same or different for the inner proximal and distal top grooves 284a′ and 284b′.
The outer top grooves 284a″ and 284b″ can have outer top groove radii of curvature 318″ from about 2.5 cm (1.0 in.) to about 7.6 cm (3.0 in.), for example about 3.8 cm (1.5 in.). The outer top groove radii of curvature 318″ can be the same or different for the outer proximal and distal top grooves 284a″ and 284b″.
a through 53d illustrate that that the components of the device 2 can be slidably assembled. A deployment tool and/or fixation rod can be inserted into the device after the component are assembled.
The device 2 can have one or more radiopaque and/or echogenic markers. For example, the device 2 can have aligned markers on the top plate 6, middle plate of ramps 108 and 96 and bottom plate. When the device 2 is in a contracted pre-deployment configuration, the markers can be located immediately adjacent to one another, for example appearing as a single marker. When the device 2 is in an expanded configuration, the markers can move apart from each other, indicating to a doctor performing the implantation and deployment procedure using visualization (e.g., x-ray or ultrasound-based) that the device 2 has expanded. Under visualization the markers can also indicate the location and orientation of the device 2.
Method of Using
The devices can be made from PEEK, any medical grade polymer or metal, or any other material disclosed herein. For example, the side ramps can be made from titanium and/or a titanium alloy and the bottom and/or top plates can be made from PEEK. The device can be coated, for example with bone morphogenic protein (BMP), ceramic, and/or any other material disclosed herein, before, during or after deployment into the target site. The device can be deployed less (e.g., minimally) invasively, over the wire, percutaneously, used with a vertebral body replacement or fusion cage, or combinations thereof. The device can be expandable and un-expandable for removal or repositioning.
When the device is positioned as desired (e.g., between adjacent vertebral plates) and expanded and/or locked, the deployment tool can then be releases from the device. The device can be configured to lock itself into place with outward expansion, wedging, or interference force when receiving a release force from the deployment tool or otherwise. For example, the device can have unidirectionally sliding teeth oppositely located on the adjacent surfaces of the wedges and plates.
A leader or wire, such as a guidewire, can be inserted or otherwise deployed into the target site, for example, the wire can be percutaneously inserted in a minimally invasive procedure. The wire can be inserted into the intervertebral space, for example between a first vertebral plate and an adjacent, second, vertebral plate. The wire can be anteriorly and/or posteriorly inserted. The wire can be laterally inserted.
Whether or not the device is inserted over or along the wire, the device can be inserted into the target site (e.g., between adjacent vertebral bodies) from an anterior, lateral, posterior, transforaminal approach, or combinations thereof.
a and 55b illustrate that the deployment tool can radially expand the device between the first vertebral end plate and the second vertebral end plate. The top plate 6 can press against and/or embed into the first vertebral end plate 234. The bottom plate 10 can press against and/or embed into the second vertebral end plate 238. The device 2 can fuse or fix the first vertebra 234 to the second vertebra 238.
a illustrates that one, two or more devices 2, such as a first device 2a and a second device 2b, can be inserted, deployed and/or implanted the target site, such as in a vertebral body 324 or on a vertebral body 324 (e.g., between adjacent vertebral bodies). The devices 2 can be oriented so the longitudinal axes 4 of the devices 2 are substantially parallel with an anterior-posterior axis 320 of the patient.
The first device 2a can be oriented so the first device longitudinal axis 4a can be substantially parallel with the anterior-posterior axis 320.
The second device 2b can be oriented so the second device longitudinal axis 4b can be substantially parallel with the anterior-posterior axis 320. The second device 2b can be positioned in a substantially symmetric location and angular orientation to the first device 2a with respect to the anterior-posterior axis 320.
The concavity of the radius of curvature 300 of the device can face toward (as shown) or away from the medial direction (i.e., the central anterior-posterior axis 320).
After placed into position at the target site, the device 2 can be longitudinally contracted and radially expanded. For example, as shown, the second device 2b has been radially expanded, and the first device 4a has been delivered to the target site and not yet radially expanded. Multiple devices 4 can be delivered concurrently or sequentially. Multiple devices 4 can be radially expanded sequentially or concurrently.
The devices 4 can be inserted with a surgical technique such as an Anterior Lumbar Interbody Fusion (ALIF), shown by arrow 322a, Posterior Lumbar Interbody Fusion (PLIF), shown by arrow 322b, Transforaminal Lumbar Interbody Fusion (TLIF), shown by arrow 322c, a direct linear lateral delivery, as shown by arrow 322d, a curvilinear lateral delivery initially inserted posteriorly, as shown by arrow 322e, or other methods or combinations thereof.
Operative planning and templating can be performed using MRI and CAT imaging scans to determine what size device fits the patient's anatomy and pathology.
The disc (i.e., intervertebral) space or other target site can then be prepared. For PLIF procedures, the vertebrae can be accessed through an incision in the patient's back (i.e., posterior to the vertebrae). Depending on the number of vertebral levels to be fused, about a 3-6 inch incision can be made in the patient's back. The spinal muscles can then be retracted (or separated), for example, to allow access to the target vertebral discs. The lamina can then be removed (i.e., a laminectomy), for example, to be able to see and access the nerve roots. The facet joints, which can lie directly over the nerve roots, can be trimmed, for example, to allow more room for the nerve roots. The target disc and surrounding tissue can then be removed and the bone surfaces of adjacent vertebrae can be prepared (e.g., cleaned, abraded, debrided, textured, scored, coated with osteogenic powders or other agents, or combinations thereof).
The devices 2 can then be inserted into the target site. One or more devices 2 and/or bone graft (e.g., autograft, allograft, xenograft), BMP, or combinations thereof, can be inserted into the target site or disc space, for example, to promote fusion between the vertebrae. Additional instrumentation (e.g., rods or screws) can also be used at this time to further stabilize the spine.
TLIF can include delivering the device 2 to the spine in a path more from the side of the spinal canal than a PLIF approach and through a midline incision in the patient's back. TLIF can reduce the amount of surgical muscle dissection and can minimizes nerve manipulation required to access the vertebrae, discs and nerves.
TLIF can include removing disc material from the spine and inserting the device(s) 2 and bone graft, BMP, screws, rods, or combinations thereof.
ALIF is performed inserting the from the front (anterior) of the body, usually through a 3-5 inch incision in the lower abdominal area or on the side. This incision may involve cutting through, and later repairing, the muscles in the lower abdomen.
A mini open ALIF approach can be performed. A mini open ALIF can preserves the muscles and allow access to the front of the spine through an incision. This approach maintains abdominal muscle strength and function and can be used to fuse the L5-S1 disc space, for example
Once the incision is made and the vertebrae are accessed, and after the abdominal muscles and blood vessels have been retracted, the disc material can be removed. The surgeon can then insert the devices 2 and/or bone graft, rods, screws, BMP, or combinations thereof, for example to stabilize the spine and facilitate fusion.
The target site for the device(s) 2 can be between sacral, lumbar, thoracic, cervical vertebrae, or combinations thereof. The target site can be between other bones, such as intercostal (between ribs), in the knee, elbow, wrist, ankle, or combinations thereof.
b illustrates that one (as shown) or more devices 2 can be inserted into the target site, such as in a vertebral body or on a vertebral body (e.g., between adjacent vertebral bodies). The longitudinal axis 4 of the device 2 can be oriented substantially perpendicular to the anterior-posterior axis 320 (i.e., parallel to a lateral axis). The concavity of the radius of curvature 300 can face anteriorly or posteriorly.
The device 2 can be filled with a filled before or after radial expansion. Tissue ingrowth can occur into the top plate through the top ports, bottom plate through the bottom ports, and elsewhere through the device.
The device 2 can provide fusion between the adjacent vertebrae. The devices 2 can have radiopaque and/or echogenic visualization markers, for example the markers can be along the top plate, bottom plate, and one or more panels of the plates. The deployment tool can also have one or more markers. The devices 2 can be inserted into multiple interbody target sites of the spine to provide fusion between adjacent vertebral bodies. A first device can be inserted into a first interbody site and a second device can be inserted into a second interbody site. The first and second devices can be inserted bilaterally, for example both devices can be inserted between the same first vertebra and second vertebra from opposite lateral sides.
Any or all elements of the device 2 and/or other devices or apparatuses described herein can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CON ICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), nickel-cobalt alloys (e.g., MP35N® from Magellan Industrial Trading Company, Inc., Westport, Conn.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published 9 Oct. 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as polyethylene teraphathalate (PET), polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), poly ester amide (PEA), polypropylene, aromatic polyesters, such as liquid crystal polymers (e.g., Vectran, from Kuraray Co., Ltd., Tokyo, Japan), ultra high molecular weight polyethylene (i.e., extended chain, high-modulus or high-performance polyethylene) fiber and/or yarn (e.g., SPECTRA® Fiber and SPECTRA® Guard, from Honeywell International, Inc., Morris Township, N.J., or DYNEEMA® from Royal DSM N.V., Heerlen, the Netherlands), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ketone (PEK), polyether ether ketone (PEEK), poly ether ketone ketone (PEKK) (also poly aryl ether ketone ketone), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Mass.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), poly-L-glycolic acid (PLGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials, a biomaterial (e.g., cadaver tissue, collagen, allograft, autograft, xenograft, bone cement, morselized bone, osteogenic powder, beads of bone) any of the other materials listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
The device 2 can be made from substantially 100% PEEK, substantially 100% titanium or titanium alloy, or combinations thereof.
Any or all elements of the device 2 and/or other devices or apparatuses described herein, can be, have, and/or be completely or partially coated with agents for cell ingrowth.
The device 2 and/or elements of the device and/or other devices or apparatuses described herein can be filled, coated, layered and/or otherwise made with and/or from cements, fillers, and/or glues known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. Any of these cements and/or fillers and/or glues can be osteogenic and osteoinductive growth factors.
Examples of such cements and/or fillers includes bone chips, demineralized bone matrix (DBM), calcium sulfate, coralline hydroxyapatite, biocoral, tricalcium phosphate, calcium phosphate, polymethyl methacrylate (PMMA), biodegradable ceramics, bioactive glasses, hyaluronic acid, lactoferrin, bone morphogenic proteins (BMPs) such as recombinant human bone morphogenetic proteins (rhBMPs), other materials described herein, or combinations thereof.
The agents within these matrices can include any agent disclosed herein or combinations thereof, including radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE®, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J. Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J. Surgery 86 (6), 771-775; Xu et al, SpI Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
Any elements described herein as singular can be pluralized (i.e., anything described as “one” can be more than one). Any species element of a genus element can have the characteristics or elements of any other species element of that genus. The above-described configurations, elements or complete assemblies and methods and their elements for carrying out the invention, and variations of aspects of the invention can be combined and modified with each other in any combination.
Number | Name | Date | Kind |
---|---|---|---|
646119 | Clamer et al. | Mar 1900 | A |
3659587 | Baldwin | May 1972 | A |
4204531 | Aginsky | May 1980 | A |
4636217 | Ogilvie et al. | Jan 1987 | A |
4653489 | Tronzo | Mar 1987 | A |
4716839 | Catena | Jan 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4759769 | Hedman et al. | Jul 1988 | A |
4763644 | Webb | Aug 1988 | A |
4863476 | Shepperd | Sep 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4911718 | Lee et al. | Mar 1990 | A |
4932975 | Main et al. | Jun 1990 | A |
4969888 | Scholten et al. | Nov 1990 | A |
4978341 | Niederhauser | Dec 1990 | A |
5007909 | Rogozinski | Apr 1991 | A |
5015247 | Michelson | May 1991 | A |
5026373 | Ray et al. | Jun 1991 | A |
5059193 | Kuslich | Oct 1991 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5123926 | Pisharodi | Jun 1992 | A |
5139480 | Hickle et al. | Aug 1992 | A |
5171278 | Pisharodi | Dec 1992 | A |
5217483 | Tower | Jun 1993 | A |
5258031 | Salib et al. | Nov 1993 | A |
5273533 | Bonaldo | Dec 1993 | A |
5342348 | Kaplan | Aug 1994 | A |
5345927 | Bonutti | Sep 1994 | A |
5360417 | Gravener et al. | Nov 1994 | A |
5390683 | Pisharodi | Feb 1995 | A |
5391153 | Haber et al. | Feb 1995 | A |
5391154 | Young | Feb 1995 | A |
5397364 | Kozak et al. | Mar 1995 | A |
5425773 | Boyd et al. | Jun 1995 | A |
5458643 | Oka et al. | Oct 1995 | A |
5480442 | Bertagnoli | Jan 1996 | A |
5484384 | Fearnot | Jan 1996 | A |
5496365 | Sgro | Mar 1996 | A |
5522899 | Michelson | Jun 1996 | A |
5534002 | Brumfield et al. | Jul 1996 | A |
5540690 | Miller et al. | Jul 1996 | A |
5549679 | Kuslich | Aug 1996 | A |
5554191 | Lahille et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5562736 | Ray et al. | Oct 1996 | A |
5562738 | Boyd et al. | Oct 1996 | A |
5571189 | Kuslich | Nov 1996 | A |
5571192 | Schonhoffer | Nov 1996 | A |
5591197 | Orth et al. | Jan 1997 | A |
5593409 | Michelson | Jan 1997 | A |
5609356 | Mossi | Mar 1997 | A |
5609635 | Michelson | Mar 1997 | A |
5634937 | Mollenauer et al. | Jun 1997 | A |
5643312 | Fischell et al. | Jul 1997 | A |
5653763 | Errico et al. | Aug 1997 | A |
5658335 | Allen | Aug 1997 | A |
5662615 | Blake, III | Sep 1997 | A |
5665122 | Kambin | Sep 1997 | A |
5669909 | Zdeblick et al. | Sep 1997 | A |
5674295 | Ray et al. | Oct 1997 | A |
5683394 | Rinner | Nov 1997 | A |
5693100 | Pisharodi | Dec 1997 | A |
5702449 | McKay | Dec 1997 | A |
5702453 | Rabbe et al. | Dec 1997 | A |
5741253 | Michelson | Apr 1998 | A |
5749916 | Richelsoph | May 1998 | A |
5772661 | Michelson | Jun 1998 | A |
5776181 | Lee et al. | Jul 1998 | A |
5776197 | Rabbe et al. | Jul 1998 | A |
5776198 | Rabbe et al. | Jul 1998 | A |
5776199 | Michelson | Jul 1998 | A |
5782832 | Larsen et al. | Jul 1998 | A |
5782903 | Wiktor | Jul 1998 | A |
5785710 | Michelson | Jul 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824093 | Ray et al. | Oct 1998 | A |
5827289 | Reiley et al. | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5853419 | Imran | Dec 1998 | A |
5861025 | Boudghene et al. | Jan 1999 | A |
5863284 | Klein | Jan 1999 | A |
5865848 | Baker | Feb 1999 | A |
5895387 | Guerrero et al. | Apr 1999 | A |
5916198 | Dillow | Jun 1999 | A |
5972015 | Scribner et al. | Oct 1999 | A |
5980522 | Koros et al. | Nov 1999 | A |
5980550 | Eder et al. | Nov 1999 | A |
5984957 | Laptewicz et al. | Nov 1999 | A |
6001130 | Bryan et al. | Dec 1999 | A |
6019792 | Cauthen | Feb 2000 | A |
6022376 | Assell et al. | Feb 2000 | A |
6025104 | Fuller et al. | Feb 2000 | A |
6027527 | Asano et al. | Feb 2000 | A |
6036719 | Meilus | Mar 2000 | A |
6039761 | Li et al. | Mar 2000 | A |
6045579 | Hochshuler et al. | Apr 2000 | A |
6066154 | Reiley et al. | May 2000 | A |
6077246 | Kullas et al. | Jun 2000 | A |
6080193 | Hochshuler et al. | Jun 2000 | A |
6083522 | Chu et al. | Jul 2000 | A |
6086610 | Duerig et al. | Jul 2000 | A |
6090143 | Meriwether et al. | Jul 2000 | A |
6102950 | Vaccaro | Aug 2000 | A |
6113639 | Ray et al. | Sep 2000 | A |
6126689 | Brett | Oct 2000 | A |
6127597 | Beyar et al. | Oct 2000 | A |
6129763 | Chauvin et al. | Oct 2000 | A |
6132465 | Ray et al. | Oct 2000 | A |
6140452 | Felt et al. | Oct 2000 | A |
6146417 | Ischinger | Nov 2000 | A |
6159244 | Suddaby | Dec 2000 | A |
6159245 | Meriwether et al. | Dec 2000 | A |
6168616 | Brown, III | Jan 2001 | B1 |
6171312 | Beaty | Jan 2001 | B1 |
6176882 | Biedermann et al. | Jan 2001 | B1 |
6179874 | Cauthen | Jan 2001 | B1 |
6183506 | Penn et al. | Feb 2001 | B1 |
6183517 | Suddaby | Feb 2001 | B1 |
6193757 | Foley et al. | Feb 2001 | B1 |
6206910 | Berry et al. | Mar 2001 | B1 |
6206924 | Timm | Mar 2001 | B1 |
6217579 | Koros | Apr 2001 | B1 |
6224595 | Michelson | May 2001 | B1 |
6224603 | Marino | May 2001 | B1 |
6224604 | Suddaby | May 2001 | B1 |
6224607 | Michelson | May 2001 | B1 |
6228060 | Howell | May 2001 | B1 |
6245101 | Drasler et al. | Jun 2001 | B1 |
6245107 | Ferree | Jun 2001 | B1 |
6280456 | Scribner et al. | Aug 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6293967 | Shanley | Sep 2001 | B1 |
6302914 | Michelson | Oct 2001 | B1 |
6332895 | Suddaby | Dec 2001 | B1 |
6371989 | Chauvin et al. | Apr 2002 | B1 |
6395031 | Foley et al. | May 2002 | B1 |
6402750 | Atkinson et al. | Jun 2002 | B1 |
6402785 | Zdeblick et al. | Jun 2002 | B1 |
6409765 | Bianchi et al. | Jun 2002 | B1 |
6419704 | Ferree | Jul 2002 | B1 |
6419705 | Erickson | Jul 2002 | B1 |
6423083 | Reiley et al. | Jul 2002 | B2 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6425919 | Lambrecht | Jul 2002 | B1 |
6428569 | Brown | Aug 2002 | B1 |
6432107 | Ferree | Aug 2002 | B1 |
6436098 | Michelson | Aug 2002 | B1 |
6436140 | Liu et al. | Aug 2002 | B1 |
6440168 | Cauthen | Aug 2002 | B1 |
6447544 | Michelson | Sep 2002 | B1 |
6447546 | Bramlet et al. | Sep 2002 | B1 |
6447547 | Michelson | Sep 2002 | B1 |
6451025 | Jervis | Sep 2002 | B1 |
6454804 | Ferree | Sep 2002 | B1 |
6454806 | Cohen et al. | Sep 2002 | B1 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6468302 | Cox et al. | Oct 2002 | B2 |
6478823 | Michelson | Nov 2002 | B1 |
6482235 | Lambrecht et al. | Nov 2002 | B1 |
6488710 | Besselink | Dec 2002 | B2 |
6491724 | Ferree | Dec 2002 | B1 |
6494883 | Ferree | Dec 2002 | B1 |
6508839 | Lambrecht et al. | Jan 2003 | B1 |
6514255 | Ferree | Feb 2003 | B1 |
6520991 | Huene | Feb 2003 | B2 |
6533817 | Norton et al. | Mar 2003 | B1 |
6554833 | Levy et al. | Apr 2003 | B2 |
6562074 | Gerbec et al. | May 2003 | B2 |
6582431 | Ray | Jun 2003 | B1 |
6582467 | Teitelbaum et al. | Jun 2003 | B1 |
6585770 | White et al. | Jul 2003 | B1 |
6592589 | Hajianpour | Jul 2003 | B2 |
6592625 | Cauthen | Jul 2003 | B2 |
6595998 | Johnson et al. | Jul 2003 | B2 |
6602291 | Ray et al. | Aug 2003 | B1 |
6607544 | Boucher et al. | Aug 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6623505 | Scribner et al. | Sep 2003 | B2 |
6641587 | Scribner et al. | Nov 2003 | B2 |
6641614 | Wagner et al. | Nov 2003 | B1 |
6645213 | Sand et al. | Nov 2003 | B2 |
6645247 | Ferree | Nov 2003 | B2 |
6648917 | Gerbec et al. | Nov 2003 | B2 |
6648918 | Ferree | Nov 2003 | B2 |
6648920 | Ferree | Nov 2003 | B2 |
6652584 | Michelson | Nov 2003 | B2 |
6656178 | Veldhuizen et al. | Dec 2003 | B1 |
6663647 | Reiley et al. | Dec 2003 | B2 |
6666891 | Boehm, Jr. et al. | Dec 2003 | B2 |
6679915 | Cauthen | Jan 2004 | B1 |
6685695 | Ferree | Feb 2004 | B2 |
6695760 | Winkler et al. | Feb 2004 | B1 |
6706068 | Ferree | Mar 2004 | B2 |
6706070 | Wagner et al. | Mar 2004 | B1 |
6709458 | Michelson | Mar 2004 | B2 |
6712853 | Kuslich | Mar 2004 | B2 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6716247 | Michelson | Apr 2004 | B2 |
6719773 | Boucher et al. | Apr 2004 | B1 |
6723126 | Berry | Apr 2004 | B1 |
6726691 | Osorio et al. | Apr 2004 | B2 |
6733535 | Michelson | May 2004 | B2 |
6743255 | Ferree | Jun 2004 | B2 |
6746451 | Middleton et al. | Jun 2004 | B2 |
6758863 | Estes et al. | Jul 2004 | B2 |
6793656 | Mathews | Sep 2004 | B1 |
6793679 | Michelson | Sep 2004 | B2 |
6808537 | Michelson | Oct 2004 | B2 |
6814756 | Michelson | Nov 2004 | B1 |
6852115 | Kinnett | Feb 2005 | B2 |
6852123 | Brown | Feb 2005 | B2 |
6852129 | Gerbec et al. | Feb 2005 | B2 |
6863673 | Gerbec et al. | Mar 2005 | B2 |
6893464 | Kiester | May 2005 | B2 |
6923830 | Michelson | Aug 2005 | B2 |
6936070 | Muhanna | Aug 2005 | B1 |
6953477 | Berry | Oct 2005 | B2 |
6955691 | Chae et al. | Oct 2005 | B2 |
6960215 | Olson et al. | Nov 2005 | B2 |
6962606 | Michelson | Nov 2005 | B2 |
7008453 | Michelson | Mar 2006 | B1 |
7018415 | McKay | Mar 2006 | B1 |
7018416 | Hanson et al. | Mar 2006 | B2 |
7056321 | Pagliuca et al. | Jun 2006 | B2 |
7060073 | Frey et al. | Jun 2006 | B2 |
7066961 | Michelson | Jun 2006 | B2 |
7077864 | Byrd et al. | Jul 2006 | B2 |
7087055 | Lim et al. | Aug 2006 | B2 |
7094257 | Mujwid et al. | Aug 2006 | B2 |
7097648 | Globerman et al. | Aug 2006 | B1 |
7112206 | Michelson | Sep 2006 | B2 |
7118598 | Michelson | Oct 2006 | B2 |
7135043 | Nakahara et al. | Nov 2006 | B2 |
7166110 | Yundt | Jan 2007 | B2 |
7201751 | Zucherman et al. | Apr 2007 | B2 |
7201775 | Gorensek et al. | Apr 2007 | B2 |
7204853 | Gordon et al. | Apr 2007 | B2 |
7211112 | Baynham et al. | May 2007 | B2 |
7212480 | Shoji et al. | May 2007 | B2 |
7223292 | Messerli et al. | May 2007 | B2 |
7226475 | Lenz et al. | Jun 2007 | B2 |
7226481 | Kuslich | Jun 2007 | B2 |
7226483 | Gerber et al. | Jun 2007 | B2 |
7238186 | Zdeblick et al. | Jul 2007 | B2 |
7241276 | Argentine et al. | Jul 2007 | B2 |
7241297 | Shaolian et al. | Jul 2007 | B2 |
7241303 | Reiss et al. | Jul 2007 | B2 |
7300440 | Zdeblick et al. | Nov 2007 | B2 |
7309338 | Cragg | Dec 2007 | B2 |
7311713 | Johnson et al. | Dec 2007 | B2 |
7316714 | Gordon et al. | Jan 2008 | B2 |
7318826 | Teitelbaum et al. | Jan 2008 | B2 |
7431735 | Liu et al. | Oct 2008 | B2 |
7503933 | Michelson | Mar 2009 | B2 |
7507241 | Levy et al. | Mar 2009 | B2 |
7582106 | Teitelbaum et al. | Sep 2009 | B2 |
7601172 | Segal et al. | Oct 2009 | B2 |
7618457 | Hudgins | Nov 2009 | B2 |
7621950 | Globerman et al. | Nov 2009 | B1 |
7722674 | Grotz | May 2010 | B1 |
7828849 | Lim | Nov 2010 | B2 |
7837734 | Zucherman et al. | Nov 2010 | B2 |
7879036 | Biedermann et al. | Feb 2011 | B2 |
7879082 | Brown | Feb 2011 | B2 |
8105382 | Olmos et al. | Jan 2012 | B2 |
8262737 | Bagga et al. | Sep 2012 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010034552 | Young et al. | Oct 2001 | A1 |
20020007218 | Cauthen | Jan 2002 | A1 |
20020010511 | Michelson | Jan 2002 | A1 |
20020022887 | Huene | Feb 2002 | A1 |
20020032444 | Mische | Mar 2002 | A1 |
20020052656 | Michelson | May 2002 | A1 |
20020068911 | Chan | Jun 2002 | A1 |
20020068939 | Levy et al. | Jun 2002 | A1 |
20020068975 | Teitelbaum et al. | Jun 2002 | A1 |
20020068976 | Jackson | Jun 2002 | A1 |
20020068977 | Jackson | Jun 2002 | A1 |
20020082598 | Teitelbaum | Jun 2002 | A1 |
20020082600 | Shaolian et al. | Jun 2002 | A1 |
20020091390 | Michelson | Jul 2002 | A1 |
20020095155 | Michelson | Jul 2002 | A1 |
20020099378 | Michelson | Jul 2002 | A1 |
20020111688 | Cauthen | Aug 2002 | A1 |
20020120337 | Cauthen | Aug 2002 | A1 |
20020123807 | Cauthen | Sep 2002 | A1 |
20020128713 | Ferree | Sep 2002 | A1 |
20020138077 | Ferree | Sep 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020138144 | Michelson | Sep 2002 | A1 |
20020143401 | Michelson | Oct 2002 | A1 |
20020151896 | Ferree | Oct 2002 | A1 |
20020151980 | Cauthen | Oct 2002 | A1 |
20020156530 | Lambrecht et al. | Oct 2002 | A1 |
20020161367 | Ferree | Oct 2002 | A1 |
20020161373 | Osorio et al. | Oct 2002 | A1 |
20020165542 | Ferree | Nov 2002 | A1 |
20020189622 | Cauthen et al. | Dec 2002 | A1 |
20020198526 | Shaolian et al. | Dec 2002 | A1 |
20030004511 | Ferree | Jan 2003 | A1 |
20030004574 | Ferree | Jan 2003 | A1 |
20030009227 | Lambrecht et al. | Jan 2003 | A1 |
20030014118 | Lambrecht et al. | Jan 2003 | A1 |
20030026788 | Ferree | Feb 2003 | A1 |
20030032963 | Reiss et al. | Feb 2003 | A1 |
20030040798 | Michelson | Feb 2003 | A1 |
20030050701 | Michelson | Mar 2003 | A1 |
20030065394 | Michelson | Apr 2003 | A1 |
20030065396 | Michelson | Apr 2003 | A1 |
20030074076 | Ferree et al. | Apr 2003 | A1 |
20030078579 | Ferree | Apr 2003 | A1 |
20030088249 | Furderer | May 2003 | A1 |
20030120345 | Cauthen | Jun 2003 | A1 |
20030125748 | Li et al. | Jul 2003 | A1 |
20030125807 | Lambrecht et al. | Jul 2003 | A1 |
20030135220 | Cauthen | Jul 2003 | A1 |
20030135279 | Michelson | Jul 2003 | A1 |
20030149482 | Michelson | Aug 2003 | A1 |
20030153976 | Cauthen et al. | Aug 2003 | A1 |
20030158553 | Michelson | Aug 2003 | A1 |
20030158604 | Cauthen et al. | Aug 2003 | A1 |
20030163200 | Cauthen | Aug 2003 | A1 |
20030181979 | Ferree | Sep 2003 | A1 |
20030181980 | Berry et al. | Sep 2003 | A1 |
20030181983 | Cauthen | Sep 2003 | A1 |
20030187507 | Cauthen | Oct 2003 | A1 |
20030187508 | Cauthen | Oct 2003 | A1 |
20030191536 | Ferree | Oct 2003 | A1 |
20030195514 | Trieu et al. | Oct 2003 | A1 |
20030195630 | Ferree | Oct 2003 | A1 |
20030195631 | Ferree | Oct 2003 | A1 |
20030199979 | McGuckin | Oct 2003 | A1 |
20030199981 | Ferree | Oct 2003 | A1 |
20030204260 | Ferree | Oct 2003 | A1 |
20030208270 | Michelson | Nov 2003 | A9 |
20030220643 | Ferree | Nov 2003 | A1 |
20030220650 | Major et al. | Nov 2003 | A1 |
20030220690 | Cauthen | Nov 2003 | A1 |
20030220693 | Cauthen | Nov 2003 | A1 |
20030220694 | Cauthen | Nov 2003 | A1 |
20030233097 | Ferree | Dec 2003 | A1 |
20030233188 | Jones | Dec 2003 | A1 |
20030236520 | Lim et al. | Dec 2003 | A1 |
20040002759 | Ferree | Jan 2004 | A1 |
20040002760 | Boyd et al. | Jan 2004 | A1 |
20040002769 | Ferree | Jan 2004 | A1 |
20040006341 | Shaolian et al. | Jan 2004 | A1 |
20040006344 | Nguyen et al. | Jan 2004 | A1 |
20040010315 | Song | Jan 2004 | A1 |
20040010318 | Ferree | Jan 2004 | A1 |
20040019386 | Ferree | Jan 2004 | A1 |
20040024400 | Michelson | Feb 2004 | A1 |
20040024459 | Ferree | Feb 2004 | A1 |
20040024460 | Ferree | Feb 2004 | A1 |
20040024461 | Ferree | Feb 2004 | A1 |
20040024462 | Ferree et al. | Feb 2004 | A1 |
20040024469 | Ferree | Feb 2004 | A1 |
20040024471 | Ferree | Feb 2004 | A1 |
20040028718 | Ferree | Feb 2004 | A1 |
20040030387 | Landry et al. | Feb 2004 | A1 |
20040030389 | Ferree | Feb 2004 | A1 |
20040030390 | Ferree | Feb 2004 | A1 |
20040030391 | Ferree | Feb 2004 | A1 |
20040030398 | Ferree | Feb 2004 | A1 |
20040034357 | Beane et al. | Feb 2004 | A1 |
20040044410 | Ferree et al. | Mar 2004 | A1 |
20040049289 | Tordy et al. | Mar 2004 | A1 |
20040059418 | McKay et al. | Mar 2004 | A1 |
20040059419 | Michelson | Mar 2004 | A1 |
20040059429 | Amin et al. | Mar 2004 | A1 |
20040068259 | Michelson | Apr 2004 | A1 |
20040082954 | Teitelbaum et al. | Apr 2004 | A1 |
20040082961 | Teitelbaum | Apr 2004 | A1 |
20040087950 | Teitelbaum | May 2004 | A1 |
20040092933 | Shaolian et al. | May 2004 | A1 |
20040092988 | Shaolian et al. | May 2004 | A1 |
20040097927 | Yeung et al. | May 2004 | A1 |
20040111108 | Farnan | Jun 2004 | A1 |
20040133229 | Lambrecht et al. | Jul 2004 | A1 |
20040133280 | Trieu | Jul 2004 | A1 |
20040138673 | Lambrecht et al. | Jul 2004 | A1 |
20040153146 | Lashinski et al. | Aug 2004 | A1 |
20040167625 | Beyar et al. | Aug 2004 | A1 |
20050010292 | Carrasco | Jan 2005 | A1 |
20050015152 | Sweeney | Jan 2005 | A1 |
20050033431 | Gordon et al. | Feb 2005 | A1 |
20050033437 | Bao et al. | Feb 2005 | A1 |
20050038512 | Michelson | Feb 2005 | A1 |
20050043796 | Grant et al. | Feb 2005 | A1 |
20050070911 | Carrison et al. | Mar 2005 | A1 |
20050080422 | Otte et al. | Apr 2005 | A1 |
20050085910 | Sweeney | Apr 2005 | A1 |
20050107863 | Brown | May 2005 | A1 |
20050113919 | Cragg et al. | May 2005 | A1 |
20050113928 | Cragg et al. | May 2005 | A1 |
20050143827 | Globerman et al. | Jun 2005 | A1 |
20050182463 | Hunter et al. | Aug 2005 | A1 |
20050187558 | Johnson et al. | Aug 2005 | A1 |
20050228391 | Levy et al. | Oct 2005 | A1 |
20050240188 | Chow et al. | Oct 2005 | A1 |
20050249776 | Chen et al. | Nov 2005 | A1 |
20050261768 | Trieu | Nov 2005 | A1 |
20050278023 | Zwirkoski | Dec 2005 | A1 |
20050278026 | Gordon et al. | Dec 2005 | A1 |
20050278036 | Leonard et al. | Dec 2005 | A1 |
20060004455 | Leonard et al. | Jan 2006 | A1 |
20060015184 | Winterbottom et al. | Jan 2006 | A1 |
20060052788 | Thelen et al. | Mar 2006 | A1 |
20060052870 | Ferree | Mar 2006 | A1 |
20060058807 | Landry et al. | Mar 2006 | A1 |
20060058876 | McKinley | Mar 2006 | A1 |
20060058880 | Wysocki et al. | Mar 2006 | A1 |
20060085069 | Kim | Apr 2006 | A1 |
20060089715 | Truckai et al. | Apr 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060106460 | Messerli et al. | May 2006 | A1 |
20060122701 | Kiester | Jun 2006 | A1 |
20060129244 | Ensign | Jun 2006 | A1 |
20060142859 | McLuen | Jun 2006 | A1 |
20060149349 | Garbe | Jul 2006 | A1 |
20060149385 | McKay | Jul 2006 | A1 |
20060161261 | Brown et al. | Jul 2006 | A1 |
20060178694 | Greenhalgh et al. | Aug 2006 | A1 |
20060184188 | Li et al. | Aug 2006 | A1 |
20060200166 | Hanson et al. | Sep 2006 | A1 |
20060206207 | Dryer et al. | Sep 2006 | A1 |
20060241764 | Michelson | Oct 2006 | A1 |
20060253201 | McLuen | Nov 2006 | A1 |
20060264968 | Frey et al. | Nov 2006 | A1 |
20060271061 | Beyar et al. | Nov 2006 | A1 |
20060276899 | Zipnick et al. | Dec 2006 | A1 |
20060287725 | Miller | Dec 2006 | A1 |
20060287726 | Segal et al. | Dec 2006 | A1 |
20060287727 | Segal et al. | Dec 2006 | A1 |
20060287729 | Segal et al. | Dec 2006 | A1 |
20060287730 | Segal et al. | Dec 2006 | A1 |
20070027363 | Gannoe et al. | Feb 2007 | A1 |
20070032791 | Greenhalgh | Feb 2007 | A1 |
20070043440 | William et al. | Feb 2007 | A1 |
20070055375 | Ferree | Mar 2007 | A1 |
20070055377 | Hanson et al. | Mar 2007 | A1 |
20070067034 | Chirico et al. | Mar 2007 | A1 |
20070093897 | Gerbec et al. | Apr 2007 | A1 |
20070093899 | Dutoit et al. | Apr 2007 | A1 |
20070112428 | Lancial | May 2007 | A1 |
20070118222 | Lang | May 2007 | A1 |
20070162135 | Segal et al. | Jul 2007 | A1 |
20070173824 | Rosen | Jul 2007 | A1 |
20070173830 | Rosen | Jul 2007 | A1 |
20070173939 | Kim et al. | Jul 2007 | A1 |
20070173940 | Hestad et al. | Jul 2007 | A1 |
20070208423 | Messerli et al. | Sep 2007 | A1 |
20070213717 | Trieu et al. | Sep 2007 | A1 |
20070233260 | Cragg | Oct 2007 | A1 |
20070244485 | Greenhalgh et al. | Oct 2007 | A1 |
20070255408 | Castleman et al. | Nov 2007 | A1 |
20070255409 | Dickson et al. | Nov 2007 | A1 |
20070270956 | Heinz | Nov 2007 | A1 |
20070270968 | Baynham et al. | Nov 2007 | A1 |
20070276377 | Yundt | Nov 2007 | A1 |
20070288028 | Gorensek et al. | Dec 2007 | A1 |
20080015694 | Tribus | Jan 2008 | A1 |
20080021558 | Thramann | Jan 2008 | A1 |
20080021559 | Thramann | Jan 2008 | A1 |
20080071356 | Greenhalgh et al. | Mar 2008 | A1 |
20080140207 | Olmos et al. | Jun 2008 | A1 |
20080147193 | Matthis et al. | Jun 2008 | A1 |
20080147194 | Grotz et al. | Jun 2008 | A1 |
20080183204 | Greenhalgh et al. | Jul 2008 | A1 |
20080188941 | Grotz | Aug 2008 | A1 |
20080221687 | Viker | Sep 2008 | A1 |
20080243254 | Butler | Oct 2008 | A1 |
20080249625 | Waugh et al. | Oct 2008 | A1 |
20080294205 | Greenhalgh et al. | Nov 2008 | A1 |
20090018524 | Greenhalgh et al. | Jan 2009 | A1 |
20090024204 | Greenhalgh et al. | Jan 2009 | A1 |
20090024217 | Levy et al. | Jan 2009 | A1 |
20090149956 | Greenhalgh et al. | Jun 2009 | A1 |
20090163918 | Levy et al. | Jun 2009 | A1 |
20090182431 | Butler et al. | Jul 2009 | A1 |
20090198338 | Phan | Aug 2009 | A1 |
20090234398 | Chirico et al. | Sep 2009 | A1 |
20100004750 | Segal et al. | Jan 2010 | A1 |
20100004751 | Segal et al. | Jan 2010 | A1 |
20100016905 | Greenhalgh et al. | Jan 2010 | A1 |
20100082109 | Greenhalgh et al. | Apr 2010 | A1 |
20100125274 | Greenhalgh et al. | May 2010 | A1 |
20100262147 | Siegal et al. | Oct 2010 | A1 |
20100292796 | Greenhalgh et al. | Nov 2010 | A1 |
20110054621 | Lim | Mar 2011 | A1 |
Number | Date | Country |
---|---|---|
0734702 | Oct 1996 | EP |
0758541 | Feb 1997 | EP |
1804733 | Jul 2007 | EP |
2874814 | Nov 2007 | FR |
2000-210315 | Aug 2000 | JP |
2002-535080 | Oct 2002 | JP |
2003-512887 | Apr 2003 | JP |
2004-511297 | Apr 2004 | JP |
2004-531355 | Oct 2004 | JP |
2004-321348 | Nov 2004 | JP |
WO 8803781 | Jun 1988 | WO |
WO 9214423 | Sep 1992 | WO |
WO 9531945 | Nov 1995 | WO |
WO 9603092 | Feb 1996 | WO |
WO 9700054 | Jan 1997 | WO |
WO 0030523 | Jun 2000 | WO |
WO 0044319 | Aug 2000 | WO |
WO 0044321 | Aug 2000 | WO |
WO 0132099 | May 2001 | WO |
WO 0178625 | Oct 2001 | WO |
WO 0195838 | Dec 2001 | WO |
WO 0213700 | Feb 2002 | WO |
WO 0232347 | Apr 2002 | WO |
WO 03003943 | Jan 2003 | WO |
WO 03003951 | Jan 2003 | WO |
WO 2005062900 | Jul 2005 | WO |
WO 2005096975 | Oct 2005 | WO |
WO 2006023514 | Mar 2006 | WO |
WO 2006023671 | Mar 2006 | WO |
WO 2006026425 | Mar 2006 | WO |
WO 2006028971 | Mar 2006 | WO |
WO 2006034396 | Mar 2006 | WO |
WO 2006034436 | Mar 2006 | WO |
WO 2006037013 | Apr 2006 | WO |
WO 2006050500 | May 2006 | WO |
WO 2006060420 | Jun 2006 | WO |
WO 2006076712 | Jul 2006 | WO |
WO 2006086241 | Aug 2006 | WO |
WO 2006096167 | Sep 2006 | WO |
WO 2006132945 | Dec 2006 | WO |
WO 2007009107 | Jan 2007 | WO |
WO 2007016368 | Feb 2007 | WO |
WO 2007038611 | Apr 2007 | WO |
WO 2007041698 | Apr 2007 | WO |
WO 2007047098 | Apr 2007 | WO |
WO 2007050322 | May 2007 | WO |
WO 2007056433 | May 2007 | WO |
WO 2007062080 | May 2007 | WO |
WO 2007075411 | Jul 2007 | WO |
WO 2007079021 | Jul 2007 | WO |
WO 2007084257 | Jul 2007 | WO |
WO 2007084268 | Jul 2007 | WO |
WO 2007084810 | Jul 2007 | WO |
WO 2007100591 | Sep 2007 | WO |
WO 2007123920 | Nov 2007 | WO |
WO 2007124130 | Nov 2007 | WO |
WO 2007126622 | Nov 2007 | WO |
WO 2007130699 | Nov 2007 | WO |
WO 2007131026 | Nov 2007 | WO |
WO 2007133608 | Nov 2007 | WO |
WO 2007140382 | Dec 2007 | WO |
WO 2008005627 | Jan 2008 | WO |
WO 2008070863 | Jun 2008 | WO |
WO 2009114381 | Sep 2009 | WO |
WO 2012027490 | Mar 2012 | WO |
Entry |
---|
Franklin, I.J. et al., “Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis,” Brit. J. Surger, 86(6):771-775, 1999. |
Pyo, R. et al., “Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms,” J. Clinical Investigation, 105(11):1641-1649, Jun. 2000. |
Tambiah, J. et al., “Provocation of Experimental Aortic Inflammation Mediators and Chlamydia pneumoniae,” Brit., J. Surgery, 88(7):935-940, Feb. 2001. |
Walton, L.J. et al., “Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms,” Circulation, 48-54, Jul. 6, 1999. |
Xu, Q. et al., “Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium,” J. Biological Chemistry, 275(32):24583-24589, Aug. 2000. |
Database WPI, Week 198004, Thomson Scientific, London, GB; AN 1980-A8866C, XP002690114, -& SU 662 082 A1 (Tartus Univ) May 15, 1979, abstract, figures 1,2. |
Number | Date | Country | |
---|---|---|---|
20110282453 A1 | Nov 2011 | US |